logo-loader
RNS
viewOmega Diagnostics Group Plc

Nigerian order for VISITECT® CD4

/**/ h1{margin-right:0cm;margin-left:0cm;font-size:24.0pt;font-family:"Times New Roman","serif";font-weight:bold;}h2{margin-right:0cm;margin-left:0cm;font-size:18.0pt;font-family:"Times New Roman","serif";font-weight:bold;}h3{margin-right:0cm;margin-left:0cm;font-size:13.5pt;font-family:"Times New Roman","serif";font-weight:bold;}h4{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight:bold;}h5{margin-right:0cm;margin-left:0cm;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight:bold;}h6{margin-top:0cm;margin-right:41.3pt;margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:justify;font-size:10.0pt;font-family:"Arial","sans-serif";color:black;font-weight:bold;}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue } visited{ color: purple } .cc{size:612.0pt 792.0pt;margin:2.0cm 42.55pt 2.0cm 42.55pt;}div.cc{}p.dm{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; text-align: center}span.dk{font-size:10.0pt;font-family:"Arial","sans-serif"}span.di{font-size:11.0pt;font-family:"Calibri","sans-serif"}p.dn{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";text-align:justify}span.dh{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black}span.dg{font-size:11.0pt; font-family:"Calibri","sans-serif"}p.do{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:36.0pt;line-height:115%;font-size:11.0pt;font-family:"Times New Roman","serif";margin-bottom:0cm;margin-bottom:.0001pt; text-align:justify;text-indent:-18.0pt;line-height:normal}span.de{font-family:Symbol} span.dd{font-family:"Calibri","sans-serif"}p.dp{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:36.0pt;line-height:115%;font-size:11.0pt;font-family:"Times New Roman","serif";margin-bottom:0cm;margin-bottom:.0001pt; text-align:justify;line-height:normal}p.dq{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-div: italic; text-align: justify}p.dr{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin-right: 41.3pt; text-align: justify}table.ds{margin-left:-5.4pt;border-collapse:collapse}tr.cu{height:11.45pt}td.cx{width:222.05pt;padding:0cm 5.4pt 0cm 5.4pt; height:11.45pt}p.dt{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; text-align: justify}td.cv{width:224.35pt;padding:0cm 5.4pt 0cm 5.4pt; height:11.45pt}p.du{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";text-align: right} tr.cr{height:12.0pt}td.ct{width:222.05pt;padding:0cm 5.4pt 0cm 5.4pt; height:12.0pt}td.cs{width:224.35pt;padding:0cm 5.4pt 0cm 5.4pt; height:12.0pt}tr.co{height:9.6pt}td.cq{width:222.05pt;padding:0cm 5.4pt 0cm 5.4pt; height:9.6pt}td.cp{width:224.35pt;padding:0cm 5.4pt 0cm 5.4pt; height:9.6pt}tr.cl{height:4.5pt}td.cn{width:222.05pt;padding:0cm 5.4pt 0cm 5.4pt; height:4.5pt}td.cm{width:224.35pt;padding:0cm 5.4pt 0cm 5.4pt; height:4.5pt}tr.ci{height:5.4pt} td.ck{width:222.05pt;padding:0cm 5.4pt 0cm 5.4pt; height:5.4pt}td.cj{width:224.35pt;padding:0cm 5.4pt 0cm 5.4pt; height:5.4pt}tr.cf{height:4.0pt}td.ch{width:222.05pt;padding:0cm 5.4pt 0cm 5.4pt; height:4.0pt}td.cg{width:224.35pt;padding:0cm 5.4pt 0cm 5.4pt; height:4.0pt}p.dv{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";text-align:justify;text-autospace:none} /**/
RNS Number : 2141V
Omega Diagnostics Group PLC
02 December 2019
 

 

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

 

Nigerian order for VISITECT® CD4

 

Omega (AIM: ODX), the medical diagnostics company focused on CD4, food intolerance and allergy testing, announces that the Company has received a second conditional purchase order for its VISITECT® CD4 350 test.

 

The order is for 200,000 tests, currently scheduled for delivery as follows, subject to the approval noted below:

 

·    50,000 tests in January 2020

·    50,000 tests in February 2020

·    100,000 tests in March 2020

 

This order is in addition to the first purchase order for 50,000 tests announced on 16 August 2019. The combined order total for 250,000 tests remains conditional upon the Nigerian Ministry of Health ("MOH") approving the Company's VISITECT® CD4 350 test into its national HIV policy, a process which is still ongoing at present. A final delivery schedule will be confirmed once the MOH outcome is known with certainty.

 

The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

Contacts: 

 

Omega Diagnostics Group PLC                         

Tel: 01259 763 030

Bill Rhodes, Interim Non-Executive Chairman

Colin King, Chief Executive                             

www.omegadiagnostics.com

Kieron Harbinson, Group Finance Director




finnCap Ltd                                              

Tel: 020 7220 0500

Geoff Nash/Hannah Boros (Corporate Finance)


Camille Gochez (ECM)




Walbrook PR Limited

Tel: 020 7933 8780 or [email protected]

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCCKCDDABDDNDB

Quick facts: Omega Diagnostics Group Plc

Price: 15.9

Market: AIM
Market Cap: £23.9 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE